2025年5月29日 周四
Home > Archive>Volume 31, Issue 3, 2023 >185-189. DOI:10.20039/j.cnki.1007-3949.2023.03.001
PDF HTML XML Export Cite reminder
Research progress of PCSK9 inhibitors in the treatment of atherosclerosis
Author:
Affiliation:

1.Department of Neurosurgery, the Third Xiangya Hospital, Central South University, Changsha, Hunan 410013, China;2.School of Biological Science and Medical Engineering, Beihang University, Beijing 100083, China;3.Department of Interventional Neuroradiology, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China)

Clc Number:

R453.9；R5

  • Article
    • | |
  • Metrics
    • |
  • Reference [29]
    • |
  • Related [20]
    • | | |
  • Comments
    Abstract:

    Proprotein convertase subtilisin/kexin 9(PCSK9) is a serine protease which can induce the degradation of low density lipoprotein receptor(LDLR), increase the level of low density lipoprotein cholesterol(LDLC) in plasma. PCSK9 participate in various mechanisms promoting atherosclerosis. Recently, a number of clinical trials have confirmed that PCSK9 inhibitors have potential anti-inflammatory, anti-platelet, atherosclerotic plaque stability and other effects. This article reviews the research progress of PCSK9 and PCSK9 inhibitors from the aspects of the structure and regulatory factors of PCSK9, and the treatment of atherosclerosis by PCSK9 inhibitors.

    Reference
    [1] DAWSON L P, LUM M, NERLEKER N, et al.Coronary atherosclerotic plaque regression:JACC state-of-the-art review.J Am Coll Cardiol, 2,9(1):66-82.
    [2] PUNCH E, KLEIN J, DIABA-NUHOHO P, et al.Effects of PCSK9 targeting:alleviating oxidation, inflammation, and atherosclerosis.J Am Heart Assoc, 2,1(3):e023328.
    [3] IGNACIO K H D, DIESTRO J D B, ENRIQUEZ C A G, et al.Predictive value of hematologic inflammatory markers in delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage.World Neurosurg, 2,0:e296-e306.
    [4] LEE S, LEE H C, KWON Y W, et al.Adenylyl cyclase-associated protein 1 is a receptor for human resistin and mediates inflammatory actions of human monocytes.Cell Metab, 4,9(3):484-497.
    [5] SEIDAH N G, PRAT A.The multifaceted biology of PCSK9.Endocr Rev, 2,3(3):558-582.
    [6] MALIGWKA M, KOSOWSKI M, HACHUA M, et al.Insight into the evolving role of PCSK9.Metabolites, 2,2(3):256.
    [7] XIAO J, BAI X Q, LIAO L, et al.Hydrogen sulfide inhibits PCSK9 expression through the PI3K/Akt-SREBP-2 signaling pathway to influence lipid metabolism in HepG2 cells.Int J Mol Med, 9,3(5):2055-2063.
    [8] HU M, HUANG X, HAN X, et al.Loss of HNF1α function contributes to hepatocyte proliferation and abnormal cholesterol metabolism via downregulating miR-122:a novel mechanism of MODY3.Diabetes Metab Syndr Obes, 0,3:627-639.
    [9] HOFMANN A, BRUNSSEN C, MORAWIETZ H.Contribution of lectin-like oxidized low-density lipoprotein receptor-1 and LOX-1 modulating compounds to vascular diseases.Vascul Pharmacol, 8,7:1-11.
    [10] HESS C N, LOW WANG C C, HIATT W R.PCSK9 inhibitors:mechanisms of action, metabolic effects, and clinical outcomes.Annu Rev Med, 8,9:133-145.
    [11] ROTH E M, DAVIDSON M H.PCSK9 inhibitors:mechanism of action, efficacy, and safety.Rev Cardiovasc Med, 8,9(S1):S31-S46.
    [12] BANERJEE Y, PANTEA STOIAN A, CICERO A F G, et al.Inclisiran:a small interfering RNA strategy targeting PCSK9 to treat hypercholesterolemia.Expert Opin Drug Saf, 2,1(1):9-20.
    [13] GOUNI-BERTHOLD I, SCHWARZ J, BERTHOLD H K.PCSK9 monoclonal antibodies:new developments and their relevance in a nucleic acid-based therapy era.Curr Atheroscler Rep, 2,4(10):779-790.
    [14] JUKEMA J W, ZIJLSTRA L E, BHATT D L, et al.Effect of alirocumab on stroke in ODYSSEY OUTCOMES.Circulation, 9,0(25):2054-2062.
    [15] PARIKH R R, BREVE F, MAGNUSSON P, et al.The use of monoclonal antibody-based proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors in the treatment of hypercholesterolemia.Cureus, 2,4(6):e25641.
    [16] SABATINE M S, GIUGLIANO R P, KEECH A C, et al.Evolocumab and clinical outcomes in patients with cardiovascular disease.N Engl J Med, 7,6(18):1713-1722.
    [17] SCHWARTZ G G, STEG P G, SZAREK M, et al.Alirocumab and cardiovascular outcomes after acute coronary syndrome.N Engl J Med, 8,9(22):2097-2107.
    [18] RAY K K, WRIGHT R S, KALLEND D, et al.Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol.N Engl J Med, 0,2(16):1507-1519.
    [19] GENNEMARK P, WALTER K, CLEMMENSEN N, et al.An oral antisense oligonucleotide for PCSK9 inhibition.Sci Transl Med, 1,3(593):eabe9117.
    [20] HOVLAND A, RETTERSTL K, MOLLNES T E, et al.Anti-inflammatory effects of non-statin low-density lipoprotein cholesterol-lowering drugs:an unused potential?.Scand Cardiovasc J, 0,4(5):274-279.
    [21] MARQUES P, DOMINGO E, RUBIO A, et al.Beneficial effects of PCSK9 inhibition with alirocumab in familial hypercholesterolemia involve modulation of new immune players.Biomed Pharmacother, 2,5:112460.
    [22] QI Z Y, HU L, ZHANG J J, et al.PCSK9 (proprotein convertase subtilisin/kexin 9) enhances platelet activation, thrombosis, and myocardial infarct expansion by binding to platelet CD36.Circulation, 1,3(1):45-61.
    [23] CAMMISOTTO V, BARATTA F, CASTELLANI V, et al.Proprotein convertase subtilisin kexin type 9 inhibitors reduce platelet activation modulating ox-LDL pathways.Int J Mol Sci, 1,2(13):7193.
    [24] MARSTON N A, GURMU Y, MELLONI G E M, et al.The effect of PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibition on the risk of venous thromboembolism.Circulation, 0,1(20):1600-1607.
    [25] NICHOLLS S J, KATAOKA Y, NISSEN S E, et al.Effect of evolocumab on coronary plaque phenotype and burden in statin-treated patients following myocardial infarction.JACC Cardiovasc Imaging, 2,5(7):1308-1321.
    [26] RBER L, UEKI Y, OTSUKA T, et al.Effect of alirocumab added to high-intensity statin therapy on coronary atherosclerosis in patients with acute myocardial infarction:the PACMAN-AMI randomized clinical trial.JAMA, 2,7(18):1771-1781.
    [27] OGATA A, OHO K, MATSUMOTO N, et al.Stabilization of vulnerable carotid plaques with proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab.Acta Neurochir (Wien), 9,1(3):597-600.
    [28] 诸骏仁, 高润霖, 赵水平, 等.《中国成人血脂异常防治指南(2016年修订版)》补充说明.中国循环杂志, 7,2(1):53.ZHU J R, GAO R L, ZHAO S P, et al.Guidelines for prevention and treatment of dyslipidemia in Chinese adults(revised edition 2016).Chin Circ J, 7,2(1):53.
    [29] GRUNDY S M, STONE N J, BAILEY A L, et al.2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol:a report of the American college of cardiology/American heart association task force on clinical practice guidelines.Circulation, 9,9(25):e1082-e1143.
    Cited by
    Comments
    Comments
    分享到微博
    Submit
Get Citation

YANG Fan, LIU Chuxuan, PENG Fei, NIU Hao, ZHANG Baorui, LIU Aihua. Research progress of PCSK9 inhibitors in the treatment of atherosclerosis[J]. Editorial Office of Chinese Journal of Arteriosclerosis,2023,31(3):185-189.

Copy
Share
Article Metrics
  • Abstract:796
  • PDF: 1062
  • HTML: 0
  • Cited by: 0
History
  • Received:July 16,2022
  • Revised:September 27,2022
  • Online: March 24,2023
Article QR Code

You are the 50320 visitor

Post Code：421001 Fax：0734-8160523

Phone：0734-8160765 E-mail：dmzzbjb@163.net

Editorial Office of Chinese Journal of Arteriosclerosis ® 2025